About Appili Therapeutics
Appili Therapeutics is a company based in Halifax (Canada) founded in 2015 was acquired by Aditx Therapeutics in April 2024.. Appili Therapeutics has raised $15.53 million across 14 funding rounds from investors including Fujifilm, Aditx Therapeutics and United States Air Force Academy. The company has 7 employees as of March 31, 2024. Appili Therapeutics offers products and services including LIKMEZ, ATI-1701, and ATI-1801. Appili Therapeutics operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
- Headquarter Halifax, Canada
- Employees 7 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Appili Therapeutics Inc Class A
-
Annual Revenue
$69.81 K (USD)-87.86as on Mar 31, 2024
-
Net Profit
$-1.82 M (USD)30.58as on Mar 31, 2024
-
EBITDA
$-6.77 M (USD)-21.54as on Mar 31, 2024
-
Total Equity Funding
$15.53 M (USD)
in 14 rounds
-
Latest Funding Round
$532.66 K (USD), Post-IPO
Nov 05, 2025
-
Investors
Fujifilm
& 6 more
-
Employee Count
7
as on Mar 31, 2024
-
Acquired by
Aditx Therapeutics
(Apr 02, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Appili Therapeutics
Appili Therapeutics is a publicly listed company on the TSX with ticker symbol APLI in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Appili Therapeutics
Appili Therapeutics offers a comprehensive portfolio of products and services, including LIKMEZ, ATI-1701, and ATI-1801. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats serious anaerobic and protozoal infections worldwide.
Potential vaccine against tularemia biothreat agent.
Addresses disfiguring skin infections globally.
Unlock access to complete
Unlock access to complete
Funding Insights of Appili Therapeutics
Appili Therapeutics has successfully raised a total of $15.53M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $532.66 thousand completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Post-IPO — $532,661
-
First Round
First Round
(25 May 2016)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Post-IPO - Appili Therapeutics | Valuation |
investors |
|
| Oct, 2023 | Amount | Grant - Appili Therapeutics | Valuation |
investors |
|
| May, 2023 | Amount | Grant - Appili Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Appili Therapeutics
Appili Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fujifilm, Aditx Therapeutics and United States Air Force Academy. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
The Lind Partners is based in New York, USA.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by the venture capital firm.
|
Founded Year | Domain | Location | |
|
Delivers expert business strategy and technology consulting services to support organizational growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Appili Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Appili Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Appili Therapeutics Comparisons
Competitors of Appili Therapeutics
Appili Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Appili Therapeutics
Frequently Asked Questions about Appili Therapeutics
When was Appili Therapeutics founded?
Appili Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Appili Therapeutics located?
Appili Therapeutics is headquartered in Halifax, Canada. It is registered at Halifax, Nova Scotia, Canada.
Is Appili Therapeutics a funded company?
Appili Therapeutics is a funded company, having raised a total of $15.53M across 14 funding rounds to date. The company's 1st funding round was a Grant of $7.3M, raised on May 25, 2016.
How many employees does Appili Therapeutics have?
As of Mar 31, 2024, the latest employee count at Appili Therapeutics is 7.
What is the annual revenue of Appili Therapeutics?
Annual revenue of Appili Therapeutics is $69.81K as on Mar 31, 2024.
What does Appili Therapeutics do?
Developer of drugs to treat infectious diseases. The companys product API-1503 is a class of 30S ribosome targeting agents for Gram-negative bacterias, API-1501 is a formulation of metronidazole, TI-2307 is a broad spectrum anti-fungal, ATI-1701 is a Tularemia vaccine, and Avigan is a broad-spectrum antiviral and therapeutic for COVID-19.
Who are the top competitors of Appili Therapeutics?
Appili Therapeutics's top competitors include Vaxcyte, Serum Institute of India and Biological E.
What products or services does Appili Therapeutics offer?
Appili Therapeutics offers LIKMEZ, ATI-1701, and ATI-1801.
Is Appili Therapeutics publicly traded?
Yes, Appili Therapeutics is publicly traded on TSX under the ticker symbol APLI.
Who are Appili Therapeutics's investors?
Appili Therapeutics has 7 investors. Key investors include Fujifilm, Aditx Therapeutics, United States Air Force Academy, The Lind Partners, and Invest Nova Scotia.
What is Appili Therapeutics's ticker symbol?
The ticker symbol of Appili Therapeutics is APLI on TSX.